Last reviewed · How we verify
Cycles N8, N5 and N6
Cycles N8, N5 and N6 are likely involved in the regulation of cell cycle progression.
Cycles N8, N5 and N6 are likely involved in the regulation of cell cycle progression. Used for Treatment of various cancers.
At a glance
| Generic name | Cycles N8, N5 and N6 |
|---|---|
| Also known as | topotecan, cyclophosphamide, etoposide |
| Sponsor | University of Cologne |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
While specific details about the mechanism of action of Cycles N8, N5 and N6 are not well-documented, it is believed that they may play a role in controlling the cell cycle, potentially through interactions with key regulatory proteins or pathways.
Approved indications
- Treatment of various cancers
Common side effects
- Fatigue
- Nausea
- Vomiting
Key clinical trials
- Combination Chemotherapy Followed by Stem Cell Transplant in High-risk Neuroblastoma Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cycles N8, N5 and N6 CI brief — competitive landscape report
- Cycles N8, N5 and N6 updates RSS · CI watch RSS
- University of Cologne portfolio CI